Your browser doesn't support javascript.
Don't Compromise Myeloma Care Due to COVID-19 Pandemic!
Munshi, Nikhil C; Anderson, Kenneth C.
  • Munshi NC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Anderson KC; Boston VA Healthcare System, Harvard Medical School, Boston, Massachusetts.
Blood Cancer Discov ; 1(3): 218-220, 2020 11.
Article in English | MEDLINE | ID: covidwho-2273275
ABSTRACT
Patients with active myeloma, especially with earlier stages of the disease, are susceptible to COVID-19 infection and can have adverse outcomes, even in those on first-line treatment. Importantly, myeloma therapy can be safely administered, and optimal control of myeloma is associated with improved outcome. See related video https//vimeo.com/486246183/559a80cfae See related article by Hultcrantz et al., p. 234.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Myeloma Type of study: Prognostic study Limits: Humans Language: English Journal: Blood Cancer Discov Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Myeloma Type of study: Prognostic study Limits: Humans Language: English Journal: Blood Cancer Discov Year: 2020 Document Type: Article